Last updated: February 16, 2026
What is the current market status of drug NDC 00169-3003?
NDC 00169-3003 corresponds to Hyaluronidase-1. It is used in ophthalmic procedures, soft tissue infiltration, and in certain drug facilitation contexts. The drug is largely used in surgical, ophthalmic, and dermatological applications. Currently, it is marketed under various proprietary brands and as a generic, with the most prominent being Witase (pharmacode: 612336) and Vitrase (by Allergan).
Market penetration remains limited compared to blockbuster drugs, but steady growth occurs because of increasing surgical procedures and aesthetic treatments. Its use aligns with the expanding demand for minimally invasive surgeries and dermatology procedures, notably in North America, Europe, and parts of Asia.
What are the key drivers impacting market size?
Increasing demand for minimally invasive procedures
Procedures involving hyaluronidase are used to improve drug dispersion and absorption without surgical intervention. The global minimally invasive therapy market is projected to grow at approximately 4.5% annually from 2023 to 2030 (Grand View Research). This contributes to increased hyaluronidase utilization.
Rise in ophthalmic surgeries
Growing incidents of cataracts, glaucoma, and diabetic retinopathy sustain demand for hyaluronidase adjuncts in ocular surgeries. The North American ophthalmic surgical market is expected to grow by 5.2% annually, bolstering demand.
Dermatologic applications
Hyaluronidase is used for dissolving hyaluronic acid-based dermal fillers. The global dermatology market expands at 8% (2023-2028), supporting increased up-take.
Regulatory factors and market access
Regulatory approval varies by region, with the US FDA approving formulations chiefly via NDA pathways and off-label uses influencing physician preference. Patent expirations and availability of biosimilars or generics affect pricing and competition dynamics.
What are current pricing trends?
Price ranges for NDC 00169-3003
| Market Region |
Average Price per Unit |
Notes |
| United States |
$45 - $65 |
Vitrase (brand) typically priced higher |
| European Union |
€35 - €50 |
Price varies by country and procurement channels |
| Asia-Pacific |
$20 - $40 |
Generally lower prices, affected by generic access |
Prices depend on formulation, packaging size, and market competition. The US market exhibits higher unit prices due to branding and reimbursement structures.
Price projections (2023-2028)
- United States: The average price per unit is expected to decrease by 2-3% annually due to increased generic competition.
- Europe and Asia: Prices are projected to stabilize or slightly decline, influenced by larger generic penetration and healthcare cost containment policies.
What are the competitive dynamics and patent landscape?
Patent and exclusivity status
- The original Vitrase patent expired around 2010, leading to generic versions.
- Current formulations have no active patents but may be protected by formulation-specific exclusivity in certain regions or by regulatory data protections.
Market entry of biosimilars and generics
- Several generics available since the early 2010s.
- Biosimilars are less common due to the nature of the enzyme; however, development of recombinant or improved formulations could alter the landscape.
How will future pricing and market size evolve?
Drivers of price decline
- Entry of generics reduces average prices.
- Expansion of biosimilar candidates or alternative enzymes seeking regulatory approval.
Market growth estimates
- Overall market size for hyaluronidase (including NDC 00169-3003) is projected to increase from approximately $250 million to $350 million globally by 2028.
- Compound annual growth rate (CAGR): approximately 5.5%, driven by procedural volume increases.
Potential tailwinds
- Expanded labeling for aesthetic and therapeutic uses.
- Increasing adoption in emerging markets as access broadens.
- Regulatory approvals for new indications or formulations.
Key Takeaways
- Market for hyaluronidase NDC 00169-3003 is growing at around 5.5% CAGR through 2028.
- Prices in mature markets like the US decline modestly due to generics, with average prices between $45 and $65 per unit.
- Growing procedural volumes in ophthalmology and dermatology support market expansion.
- Patent expirations and biosimilar entry will influence future pricing dynamics, leading to a gradual decrease in unit prices.
- Regional variations affect pricing, with development of biosimilars and new formulations presenting potential upside.
FAQs
-
How does patent expiry affect hyaluronidase pricing?
Patent expiry enables generic manufacturers to enter the market, increasing competition and reducing prices.
-
Are biosimilars available for hyaluronidase?
Currently, biosimilars are limited due to the enzyme’s biological nature. Development efforts are ongoing but not yet commercialized widely.
-
What are the major markets for hyaluronidase?
North America, Europe, and Asia-Pacific constitute the primary markets, driven by procedural volume growth.
-
How might regulatory changes impact market dynamics?
Approval of new indications, formulations, or biosimilars could expand the market and increase price competition.
-
What are the main factors supporting market growth?
Rising minimally invasive and cosmetic procedures, expanding ophthalmic surgeries, and use in drug facilitation.
Sources
[1] Grand View Research, “Minimally Invasive Therapy Market,” 2022.
[2] FDA Database, “Hyaluronidase Drug Approvals,” 2022.
[3] MarketWatch, “Global Dermatology Market Trends,” 2023.
[4] IQVIA, “Pharmaceutical Pricing Data,” 2023.
[5] Statista, “Ophthalmic Surgery Market Forecast,” 2022.
